Navigation Links
NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®
Date:6/5/2011

ss release remain subject to audit and confirmation procedures, and therefore the results may change materially and adversely after such procedures are completed; (vi) the data in this press release is not necessarily predictive of the outcome of the expansion arm of the Phase 2 study of NKTR-102 in patients with platinum resistant/refractory ovarian that have received prior treatment with PLD—therefore the results from this expanded Phase 2 study population could be materially and adversely different than the results described in this press release; (vii) additional important data will be reported by Nektar in the future regarding the Phase 2 NKTR-102 clinical study in ovarian cancer (including without limitation the expansion arm of the study) and therefore the future results from this ongoing Phase 2 ovarian cancer study may differ materially and adversely from the preliminary interim results presented in this press release; (viii) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (ix) the uncertain outcome of any future intellectual property, commercial or other litigation related to Nektar's proprietary product candidates, including without limitation NKTR-102; and (x) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, filed with the Securities and Exchange Commission on April 29, 2011.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, including but not limited to any clinical, FDA or other regulatory information, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nekta
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
2. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
3. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
4. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
10. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
11. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 3, 2015 Today, the ... Internet. As markets become ever more transparent, the importance ... AG recognised long ago. Its maxim of "innovation brings ... networking and digitisation. The company has long ... "state of the art" technology and modern approach, while ...
(Date:6/2/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... of products for the treatment of central nervous system ... M.D., Vanda,s President and CEO, will deliver a corporate ... New York City on Thursday, June ... The presentation at the Jefferies Global Healthcare Conference will ...
(Date:6/2/2015)... N.C. , June 2, 2015 Kewaunee ... Board of Directors declared a quarterly cash dividend of ... 2015 to stockholders of record at the close of ... Kewaunee Scientific Founded in 1906, Kewaunee Scientific ... manufacture, and installation of laboratory, healthcare, and technical furniture ...
Breaking Medicine Technology:
... Sweden, September 1 Calabar AB, a privately,held ... announced a EUR 350,000 equity financing from the ... Calabar,s product,through a phase II study with repeated ... drug on the minor glands will lead to ...
... 1 Biosensors,International Group, Ltd ("Biosensors", "Company"), ... drug-eluting stent,developed by Biosensors, has demonstrated equal ... Johnson,s industry leading drug-eluting stent, CYPHER,SELECT(TM) ("Cypher"), ... The results of the landmark study were ...
Cached Medicine Technology:Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 2Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First 'Real World, All Comers' Clinical Study 3
(Date:6/2/2015)... CA (PRWEB) June 02, 2015 ... system was released to public yesterday, and has ... Internet. HonestyFirstReviews.com's senior product reviewer Tiffany Hendricks has ... detailed review of the course on her website ... courses available for Internet marketers looking to hone ...
(Date:6/2/2015)... 02, 2015 On March 19th, 2015, ... in the Hall of Legends at Detroit’s Ford Field. ... speaker Herman Moore, the goal of the conference was ... today’s society, highlight the benefits of effective professional rehabilitation ... about the options that are available to them in ...
(Date:6/2/2015)... The Down Syndrome Association of Wisconsin ... hit show Glee as the keynote speaker for its ... Prairie, WI. The event aims to raise funds to ... and Walworth counties. , "We couldn't ... this important event," says Dawn Nuoffer, DSAW Executive Director. ...
(Date:6/2/2015)... The Horizon Blue Cross Blue Shield of ... and Wellness Challenge, held this past weekend during the ... $3,000 for the Boys & Girls Club of Atlantic ... steps on her fitbit during her play at the ... in Galloway Township. , When added to Horizon ...
(Date:6/2/2015)... June 02, 2015 “ Radaris ” was ... takes a look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... data they need on a person. , According to Psychology ... even goes on to explain that curiosity is a part ...
Breaking Medicine News(10 mins):Health News:100K Factory - Review of Aidan Booth and Steve Clayton's New IM System Published 2Health News:Rehabilitation Facility Graduate Shares Her Story at "Fighting Addiction Together" Conference 2Health News:Glee star Lauren Potter helps Down Syndrome Association of WI raise awareness, support 2Health News:LPGA’s Natalie Gulbis Raises an Additional $3,000 for the Boys & Girls Club of Atlantic City Through Horizon BCBSNJ’s Walking and Wellness Challenge 2Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2
... 19th century, Jean-Martin Charcot, the celebrated neurologist, developed a ... reported improvements in his patients, but he died shortly ... was never conducted. Now, a group of neurological ... work in a study to see if Charcot,s observation ...
... the more than 36 million people plagued by tinnitus, ... worsening the functional and emotional toll of chronic ringing, ... according to a new study from Henry Ford Hospital ... between insomnia and the severity of perceived tinnitus symptoms, ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, April ... Wednesday issued the first national standards to curb air pollution ... to hydraulic fracturing, a way to obtain natural gas by ... release gas. Natural gas is being touted by ...
... two years later, Sarah Clark grimaces sheepishly and insists she ... "I was woefully unprepared," says Clark, a researcher ... Skyline High School in Ann Arbor. "I did not do ... math homework that night. I sent him to school the ...
... , This press release is available in ... conducted with thousands of local teenagers by University of ... or ecstasy (MDMA) at fifteen or sixteen years of ... symptoms the following year. "Our findings are consistent with ...
... Lisa Esposito HealthDay Reporter , WEDNESDAY, April 18 ... a specific number of fights and years in the ring ... head without brain damage, a new study suggests. But, ... show. "The brain can tolerate or absorb a ...
Cached Medicine News:Health News:19th century therapy for Parkinson's disease may help patients today 2Health News:Study: Insomnia takes toll on tinnitus patients 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 2Health News:EPA to Cut Air Pollution from Natural Gas 'Fracking' 3Health News:Football helmet sensors help researchers demystify concussion in young athletes 2Health News:Speed and ecstasy associated with depression in teenagers 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 2Health News:When Does Boxing-Related Head Trauma Become Too Much? 3
Designed to lift corneal cap/flap during corneal lamellar surgery...
... Refractive drape has two perforations ... adapts to various single or ... draping. Refractive drape has two ... Drape adapts to various single ...
Unique 2 in 1 design allows simultaneous absorption of excess fluid & protection of flap & hinge, Lint-free PVAmaterial....
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: